Terminated/Withdrawn
Sponsor ID
20090403
Study to assess the long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Psoriasis
Study Details
This study is an open-label extension of study 20090062 to evaluate extended subcutaneous dosing of AMG 827 for up to 362 weeks.
Protocol Summary
Primary Outcome Measures
Adverse events
Timeframe: 362 weeks
Change in laboratory parameters and vital signs
Timeframe: 360 weeks
Secondary Outcome Measures
The proportion of subjects with a static physician’s global assessment (sPGA) of clear (0) or clear/almost clear (0 or 1)
Timeframe: 360 weeks
Percent improvement in Psoriasis Area and Severity Index (PASI)
Timeframe: 360 weeks
The proportion of subjects with a 50% improvement in PASI (PASI 50), PASI 75, PASI 90, and PASI 100
Timeframe: 360 weeks
Body surface area (BSA) involvement
Timeframe: 360 weeks
Study Documents
Study Synopsis
Available Language(s): English
Locations
Location
Research Site
Prahran, VIC, Australia, 3181
Status
Recruiting
Location
Research Site
Adelaide, SA, Australia, 5000
Status
Recruiting
Location
Research Site
Parkville, VIC, Australia, 3050
Status
Recruiting
Location
Research Site
Kogarah, NSW, Australia, 2217
Status
Recruiting
Location
Research Site
Waterloo, ON, Canada, N2J 1C4
Status
Recruiting
Location
Research Site
Markham, ON, Canada, L3P 1A8
Status
Recruiting
Showing {first} - {last} of {total} Results